The Age of Biology Has Begun.
AI is turning biology into an engineering discipline. Humain Ventures backs founders building the future of therapeutics, prevention, and human health.
Early partner · Deep technical underwriting · High-conviction support
What we believe
Building the Future of Human Health
Three convictions drive where we invest and how we partner with founders.
- Tech Bio
Biology Is Becoming an Engineering Discipline
Computation, AI, and programmable biology are converging to change how drugs are built and disease is treated. Teams that treat biology as a design space will define the next era of therapeutics. This is not Biotech. It is Tech Bio.
- AI-native therapeutics
- Core Tech Bio infrastructure
- The Lifespan Project
Fixing the Incentives
Outcomes follow incentives. The healthcare system rewards treatment over prevention. Founders who re-architect these incentives can reshape entire markets — and extend human healthspan.
- Prevention-first health systems
- Lifelong health accounts
- Consumer Health
Consumers Should Choose
Wearables and longitudinal data turn health from episodic care into a continuous product surface. When consumers own their data and can act on it, they become the most powerful force in healthcare.
- Wearables & continuous biosensing
- Consumer-owned health data
“Biology is ready for its ChatGPT moment.”
Eric SchmidtFormer CEO, Google“The most important application of AI is biology.”
Jensen HuangCEO, NVIDIA“The greatest innovations of the next decade will be at the intersection of AI and biology.”
Steve JobsCo-Founder, Apple
Portfolio
Companies Building the Future of Health
- Leading macrocyclic peptide platform
- $3.5B+ in pharma partnerships since investment
- Orally available 'Goldilocks' drugs
AI + chemistry unlocking undruggable targets.
Why we're excited about Unnatural Products- 100–1000× efficiency gains
- Lower energy, less data, faster iteration
Foundational intelligence layer for Tech Bio.
Why we're excited about Cognitive Scientific- Rapid, digital clinical trials
- Proof-as-a-service for the $480B supplement industry
Clinical-grade validation for consumer health.
Why we're excited about Radicle Science- EEG-enabled sleep earbuds
- Real-time brainwave monitoring
- Deep sleep optimization
Continuous brain measurement as a health platform.
Why we're excited about NextSense- Genome, records and clinical data synthesized in one review
- Patient review cut from four hours to under ten minutes
AI that frees physicians to practice, not replaces them.
Why we're excited about Profile Health- Production models without a data-science team
- No-code dashboard, MCP server and REST API
Proprietary models for teams that own the data.
Why we're excited about Impulse Labs- Toilet-mounted electrochemical biosensor
- No test strips, no compliance burden
Continuous chemistry instead of annual snapshots.
Why we're excited about Trace Health- 15M+ monthly downloads, built into LangChain and LlamaIndex
- Chroma Cloud and the Context-1 search-agent model
The context layer for AI agents.
Why we're excited about Chroma- Medicare Advantage plans with its own care delivery
- Expanding to 34 states and 1,341 counties
Health insurance rebuilt around the member, not the claim.
Why we're excited about Devoted Health- Gives cells an extra, synthetic nucleus
- Reaches 10× more genes than traditional methods
Gene therapy that goes beyond delivering a single gene.
Why we're excited about Reactosome
The Lifespan Project
Reimagining healthcare incentives
Co-founded by Aneil Mallavarapu and Linea Avey, The Lifespan Project explores a prevention-first healthcare architecture that aligns incentives across consumers, insurers, and innovators.
Profile Health is the lead example.
- Lifelong health accounts
- Prevention-aligned economics
- Consumer-owned health data
- AI-guided health management
A new financial architecture for human longevity.
In the News
Reading & Watching
- VideoBiology will be the biggest application of AIJensen Huang · YouTube
- PodcastBuilding and monetizing tech bio platformsAneil on the Spark Time Podcast · Spotify
- ArticleWe Need to Be Ready for Biology's ChatGPT MomentEric Schmidt · Time Magazine
- PodcastDeep Future: What is Tech Bio?Aneil Mallavarapu and Pablos Holman · Deep Future
- ArticleTech Bio Does DrugsAneil Mallavarapu · Humain Ventures
- ArticleThe Great Progression: The Age of BiologyPeter Leyden (Former Managing Editor, Wired) · Substack
- ArticleThe Rise of Wet AIAneil Mallavarapu · Proto-Life
For Founders
Why Founders Work With Us
A different kind of early partner.
- Deep technical underwriting
- Platform-level thinking (not single-asset bets)
- Engineering-first product intuition
- Prevention-oriented worldview
- Small, focused, high-conviction portfolio
- Hands-on support at company formation stage
What we can help with
- Technical diligence + roadmap
- Research & clinical strategy
- Partnerships & hiring
Leadership
Experienced Builders of Category-Defining Companies

Linea Avey
- Co-Founder, 23andMe
- Board of Fellows, Stanford School of Medicine
- Founding Board, Rock Health
- Director, Human Immunome Project
- Advisor, Verily Life Sciences
Built category-defining consumer health platforms.

Aneil Mallavarapu, PhD
- Mathematical biologist; award-winning scientist
- Serial entrepreneur (5× founder)
- AI, systems biology, drug engineering
Applies computation to biological complexity.

Michael Staton
- GP at Learn Capital for 8 years; grew AUM from ~$40M to ~$1.2B
- Cofounder & GP, LearnStart, Learn Capital's seed fund
- $400M+ LP capital raised; 220+ portfolio companies across platforms
- 12 unicorns from ~90 early-stage conviction investments
- 4 IPOs: Coursera, Udemy, Nerdy, Chime
Fund formation, portfolio and LP stewardship.